文献速递心脑血管急症重症综合管理与镇静镇痛

新型血清生物标志物预测接受目标温度管理的心脏骤停后患者神经结局

Novel serum biomarkers for predicting neurological outcomes in postcardiac arrest patients treated with targeted temperature management.
PubMed 文献 · Crit Care · 2023-03-16
一句话结论院外心脏骤停接受目标温度管理且未撤除生命支持治疗的患者中,新型血清生物标志物在心脏骤停后72小时预测不良神经结局能力最强,NFL在72小时敏感度77.1%且特异度100%。

本研究为前瞻性观察性研究,纳入2018年8月至2020年5月接受目标温度管理的院外心脏骤停患者100例,其中46例在心脏骤停后6个月神经结局良好。在自主循环恢复后0、24、48、72小时采用SIMOA免疫分析法检测传统标志物神经元特异性烯醇化酶和S100钙结合蛋白B,以及新型标志物tau蛋白、神经丝轻链(NFL)、胶质纤维酸性蛋白(GFAP)和泛素羧基末端水解酶L1(UCH-L1)。所有标志物均能区分良好与不良神经结局组(p < 0.001),新型标志物曲线下面积在心脏骤停后72小时最高(Tau 0.906、NFL 0.946、GFAP 0.875、UCH-L1 0.935),NFL在72小时预测不良神经结局的敏感度最高(77.1%,95% CI 59.9-89.6),同时保持100%特异度。

要点

  • 在未撤除生命支持治疗的院外心脏骤停接受目标温度管理患者中,新型血清生物标志物可可靠预测不良神经结局。
  • 心脏骤停后72小时新型标志物曲线下面积最高:Tau 0.906、NFL 0.946、GFAP 0.875、UCH-L1 0.935。
  • NFL在心脏骤停后72小时预测不良神经结局的敏感度最高(77.1%,95% CI 59.9-89.6),同时保持100%特异度。
  • 传统标志物与新型标志物均能区分良好与不良神经结局组(p < 0.001)。
  • 研究采用两项大型研究(TTM和COMACARE子研究)的截断值进行外部验证。

适用人群与场景

  • 接受目标温度管理的院外心脏骤停患者,纳入100例,2018年8月至2020年5月。
  • 预测时未撤除生命支持治疗。

处置流程与药物剂量

  • 在自主循环恢复后0、24、48、72小时采用SIMOA免疫分析法检测传统标志物神经元特异性烯醇化酶和S100钙结合蛋白B,以及新型标志物tau蛋白、NFL、GFAP和UCH-L1。

研究设计与关键结果

  • 前瞻性观察性研究,纳入100例院外心脏骤停接受目标温度管理患者,其中46例在心脏骤停后6个月神经结局良好。
  • 所有传统和新型血清标志物均能区分良好与不良神经结局组(p < 0.001)。
  • 新型血清标志物曲线下面积在心脏骤停后72小时最高:Tau 0.906、NFL 0.946、GFAP 0.875、UCH-L1 0.935。
  • NFL在心脏骤停后72小时预测不良神经结局的敏感度最高(77.1%,95% CI 59.9-89.6),同时保持100%特异度。
  • 研究采用两项大型研究(TTM和COMACARE子研究)的截断值进行外部验证。

证据类型、等级与局限

  • 证据类型:前瞻性观察性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在未撤除生命支持治疗的院外心脏骤停接受目标温度管理患者中,新型血清生物标志物可可靠预测不良神经结局,预测能力在心脏骤停后72小时最高。
  • 研究采用两项大型研究(TTM和COMACARE子研究)的截断值进行外部验证。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To determine the clinical feasibility of novel serum biomarkers in out-of-hospital cardiac arrest (OHCA) patients treated with target temperature management (TTM).

METHODS: This study was a prospective observational study conducted on OHCA patients who underwent TTM. We measured conventional biomarkers, neuron‑specific enolase and S100 calcium-binding protein (S-100B), as well as novel biomarkers, including tau protein, neurofilament light chain (NFL), glial fibrillary acidic protein (GFAP), and ubiquitin C-terminal hydrolase-L1 (UCH-L1), at 0, 24, 48, and 72 h after the return of spontaneous circulation identified by SIMOA immunoassay. The primary outcome was poor neurological outcome at 6 months after OHCA.

RESULTS: A total of 100 patients were included in this study from August 2018 to May 2020. Among the included patients, 46 patients had good neurologic outcomes at 6 months after OHCA. All conventional and novel serum biomarkers had the ability to discriminate between the good and poor neurological outcome groups (p < 0.001). The area under the curves of the novel serum biomarkers were highest at 72 h after cardiac arrest (CA) (0.906 for Tau, 0.946 for NFL, 0.875 for GFAP, and 0.935 for UCH-L1). The NFL at 72 h after CA had the highest sensitivity (77.1%, 95% CI 59.9-89.6) in predicting poor neurological outcomes while maintaining 100% specificity.

CONCLUSION: Novel serum biomarkers reliably predicted poor neurological outcomes for patients with OHCA treated with TTM when life-sustaining therapy was not withdrawn. Cutoffs from two large existing studies (TTM and COMACARE substudy) were externally validated in our study. The predictive power of the novel biomarkers was the highest at 72 h after CA.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Song H, Bang HJ, You Y, et al. Novel serum biomarkers for predicting neurological outcomes in postcardiac arrest patients treated with targeted temperature management. Crit Care. 2023. PMID: 36927495. doi:10.1186/s13054-023-04400-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。